Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2013

01-05-2013 | Short Communication

Dodging a dogma: is treating beyond progression beneficial?

Authors: Aung Naing, Razelle Kurzrock

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2013

Login to get access

Excerpt

Our current practice in oncology is to stop a treatment when a patient demonstrates primary resistance (tumor fails to response) or secondary resistance (tumor responds initially but later progresses). However, emerging data suggest that it may be time to challenge this dogma with a different approach. …
Literature
1.
Extra JM, Antoine EC, Vincent-Salomon A et al (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15:799–809PubMedCrossRef
2.
von Minckwitz G, du Bois A, Schmidt M et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study. J Clin Oncol 27:1999–2006CrossRef
3.
Naing A, Kurzrock R (2010) Chemotherapy resistance and retreatment: a dogma revisited. Clin Colorectal Cancer 9:E1–E4PubMedCrossRef
4.
Naing A, Lorusso P, Fu S et al (2012) Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors. Clin Cancer Res 18(9):2625–2631PubMedCrossRef
5.
Desai J, Shankar S, Heinrich MC et al (2007) Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res 13:5398–5405PubMedCrossRef
6.
Bruchovsky N, Goldenberg SLK, Gleave ME (1997) Intermittent hormonal therapy for prostate cancer. In: McGuire E (ed) Advances in urology, vol 10. Mosby-Year Book, St Louis, pp 291–326
7.
Becker A, Crombag L, Heideman DA et al (2011) Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 47:2603–2606PubMedCrossRef
8.
Santini D, Vincenzi B, Addeo R et al (2012) Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol 23:2313–2318PubMedCrossRef
9.
Igarashi T, Ohtsu T, Fujii H et al (2001) Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 73:213–221PubMedCrossRef
10.
Di Lorenzo G, Buonerba C, Faiella A et al (2011) Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 107:234–239PubMedCrossRef
11.
Buchanan GR, Rivera GK, Boyett JM et al (1988) Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study. Blood 72:1286–1292PubMed
Metadata
Title
Dodging a dogma: is treating beyond progression beneficial?
Authors
Aung Naing
Razelle Kurzrock
Publication date
01-05-2013
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-013-2123-z

Other articles of this Issue 5/2013

Cancer Chemotherapy and Pharmacology 5/2013 Go to the issue

Original Article

A preclinical study on the protective effect of melatonin against methotrexate-induced small intestinal damage: effect mediated by attenuation of nitrosative stress, protein tyrosine nitration, and PARP activation

Original Article

A phase I pharmacokinetic study of PM00104 (Zalypsis®) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors

Original Article

Physiologically based pharmacokinetic models for everolimus and sorafenib in mice

Original Article

Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1

Original Article

Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors

Original Article

Minor role of pregnane-x-receptor for acquired multidrug resistance in head and neck squamous cell carcinoma in vitro
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits